Navigation Links
Vanishing bile duct syndrome secondary to anti-retroviral therapy in HIV
Date:7/30/2010

Vanishing bile duct syndrome (VBDS) refers to a group of disorders characterized by destruction and disappearance of intrahepatic (inside the liver) bile ducts. Multiple causes have been identified including infections, malignancies, autoimmune conditions and adverse effects of medications. The usual course of this condition is variable and many patients with VBDS respond to treatment of the underlying condition and/ or removal of the offending agent. However, others progress to cirrhosis and end stage liver disease requiring liver transplantation.

VBDS is rare in patients with HIV infection, and only one case has been reported in the literature, that of an HIV patient with advanced disease and cytomegalovirus infection. In addition, there are no reports of nevirapine, an anti-retroviral (anti-HIV) drug causing VBDS even though hepatotoxicity is an important side effect of the drug.

A case report to be published on July 14, 2010 in the World Journal of Gastroenterology describes VBDS secondary to nevirapine use in an HIV-positive, pregnant female. The patient received care at the University of Texas, Memorial Hermann Hospital and the Texas Liver Center in Houston by Dr. Rajan Kochar and colleagues. A 28-yr-old African American female in the 3rd trimester of pregnancy presented to the emergency room with jaundice and itching for 3 days. She also complained of pruritus, light colored stools and dark urine. She was diagnosed with HIV infection in 2000 and had not been on highly active anti-retroviral therapy (HAART) since 2003, but recently started triple drug therapy to minimize risk of vertical transmission with zidovudine, lamivudine and nevirapine 4 wk prior to presentation. She had no history of any opportunistic infections and was not taking any prophylactic medications. Liver tests were abnormal and after liver biopsy was performed, a diagnosis of vanishing bile duct syndrome (VBDS) was made. Liver transplant evaluation was subsequently initiated for the patient.

The most likely cause of VBDS in this patient was drug-induced liver injury (DILI). Nevirapine, a non-nucleoside reverse transcriptase inhibitor, is being increasingly used in pregnant patients owing to its favorable side effect profile and lower teratogenicity compared to protease inhibitors. However, hepatotoxicity is the major adverse effect of nevirapine (5%) and most often manifests as a hypersensitivity reaction with fever, rash and elevated liver tests within the first few weeks of therapy. Late onset hepatotoxicity after several weeks of nevirapine use has also been described in several cases and may be an idiosyncratic reaction to the drug. Although several case reports have demonstrated a cholestatic pattern of nevirapine toxicity, VBDS has never been reported. Ms. B did not have fever and rash, but had evidence of cholestatic hepatitis and a temporal association between nevirapine use and development of biochemical abnormalities. Therefore, nevirapine toxicity was felt to be the most likely cause of cholestasis and VBDS.

To the best of the authors' knowledge, this is the first reported case of nevirapine induced cholestatic hepatitis in a patient with HIV leading to severe ductopenia and VBDS. Therefore, VBDS should be considered in all HIV patients with chronic cholestasis, especially those with a history of nevirapine use. In addition, the possibility of this potentially irreversible adverse event should be kept in mind before making the decision to prescribe nevirapine.


'/>"/>

Contact: Lin Tian
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Related medicine news :

1. Health Insurance Competition Vanishing: Study
2. Study finds structural brain alterations in patients with irritable bowel syndrome
3. LSUHSC study finds early predictors of metabolic syndrome in healthy 7-9 year-olds
4. Low vitamin D linked to the metabolic syndrome in elderly people
5. Upcoming Simulcast to Teach Women How to Lose Weight and Naturally Balance Hormones with Polycystic Ovarian Syndrome
6. Women with polycystic ovary syndrome have higher BPA blood levels
7. Metabolic syndrome in living kidney donors worsens function of remaining kidney
8. Vitamin D Deficiency Linked to Diabetes, Metabolic Syndrome in Studies
9. Renowned Geneticist Heralds in New Era for People with Down Syndrome
10. Women with Polycystic Ovarian Syndrome and Insulin Resistance can Lose Weight and Balance Hormones Naturally with Katie Humphrey's New E-book
11. Kids With Down Syndrome Might Get Help Learning
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2016)... ... ... When faced with having to use a toilet away from home an inventor ... contamination of children when they use public toilets. This inspired her to design a ... , The patent-pending SANI-POCKET enables a person to use a public toilet in a ...
(Date:12/9/2016)... Cincinnati, Ohio (PRWEB) , ... December 09, 2016 ... ... production of miniature, folded, pharmaceutical inserts and outserts. As a means of ... This addition will enable Flottman to individually code professional inserts (PIs) and ...
(Date:12/9/2016)... PA (PRWEB) , ... December 09, 2016 , ... An ... permit amputees to safely ride all types of amusement park rides. , The patent-pending ... the unit is easy to use and could be set up in a matter ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time ... Winchester, Va. "I thought that if the nebulizer had a more child-friendly design, then ... them." , He developed the patent-pending NEBY to avoid the need to deliver medication ...
(Date:12/8/2016)... ... December 08, 2016 , ... After ... officially opened registration today for its 33rd Annual Issues & Research Conference, ... , The theme of the conference is “Persistent Challenges and New Opportunities: Using ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Connecticut , 8 de dezembro de 2016  A Mederi Therapeutics ... terapia Stretta, um tratamento não cirúrgico para a doença do refluxo gastroesofágico (DRGE). ... ... Live Stretta procedure performed and ... of Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)... , Dec. 8, 2016 Bodycad ... patents for improving the accuracy, reproducibility and speed ... in long and small bone orthopaedic applications. These ... to creating personalized orthopaedic restorations based on each ... orthopaedic restorations, the company harnesses the world,s first ...
(Date:12/8/2016)... 8, 2016  Valeant Pharmaceuticals International, Inc. (NYSE: ... today announced positive results from a Phase 3, ... the safety and efficacy of IDP-118 (halobetasol propionate ... psoriasis. Within the Phase 3 ... severe psoriasis, IDP-118 showed statistical significance to vehicle ...
Breaking Medicine Technology: